Access in all areas? A round-up of developments in market access and health technology assessment: part 10 [0.03%]
处处有门道？市场准入和卫生技术评估的新进展概览（第十部分）
Sreeram V Ramagopalan,Annie Jullien Pannelay
Sreeram V Ramagopalan
In this update, we examine the US' Food and Drug Administration (FDA) Commissioner's National Priority Voucher pilot program; The Netherlands' Zorginstituut Nederland (ZIN) implementation framework for the EU HTA Regulation; and Italy's Age...
Safety of early postoperative showering in level-1 and level-2 surgical wounds: a retrospective study [0.03%]
一级和二级手术伤口早期术后淋浴的安全性：一项回顾性研究
Yao-Ting Chang,Chih-Sheng Lai,Su-Lan Liu et al.
Yao-Ting Chang et al.
Aim: Surgical site infections pose a significant challenge in postoperative care, traditionally managed by keeping wounds dry. However, recent studies indicate that early postoperative showering may not increase infection risk. This study a...
Matching-adjusted indirect comparisons of diroximel fumarate, ocrelizumab and interferon beta-1a for relapsing multiple sclerosis [0.03%]
基于匹配调整间接比较的二甲卡梅尔酸酯、奥克雷珠单抗和干扰素β-1a治疗复发性多发性硬化症的疗效分析研究
Carrie M Hersh,Yolanda Aladro-Benito,James B Lewin et al.
Carrie M Hersh et al.
Aim: This study compares the efficacy of diroximel fumarate (DRF) with ocrelizumab (OCR) and interferon beta-1a (IFNβ-1a) for treating relapsing multiple sclerosis (MS) through matching-adjusted indirect comparisons (MAICs). Materials & me...
Composite endpoints in health technology assessment: part 2 - expanding the evidence base with a framework for best modeling practice [0.03%]
健康技术评估中的复合终点：第2部分——用最佳建模实践框架拓展证据基础
Andrew Briggs,Jieling Chen,David Booth et al.
Andrew Briggs et al.
The first paper of this two-part series critically examined the role of composite endpoints in health technology assessments (HTAs) and outlined strategies for determining whether to employ the composite estimate of treatment effect or disa...
Composite endpoints in health technology assessment: Part 1 - an illustration of best modeling practice [0.03%]
健康技术评估中的复合终点：第1部分——最佳建模实践的说明
Andrew Briggs,Aris Angelis,Jieling Chen et al.
Andrew Briggs et al.
Composite endpoints amalgamate multiple clinical outcomes into a single measure, offering efficiency gains in clinical trials through increased event rates and reduced sample sizes, thus accelerating clinical development and regulatory appr...
How much do ex-US revenues make a difference for pharmaceutical investment returns? [0.03%]
新兴市场收入对制药业投资回报的影响几何？
Sreeram V Ramagopalan,Harshal Thaker,Mel Walker et al.
Sreeram V Ramagopalan et al.
Matching-adjusted indirect comparison of ribociclib + nonsteroidal aromatase inhibitor versus abemaciclib + endocrine therapy in hormone receptor-positive/HER2-negative early breast cancer [0.03%]
利伯西利联合非甾体芳香化酶抑制剂与阿贝西利联合内分泌治疗在激素受体阳性/HER2阴性早期乳腺癌中的匹配调整间接比较研究
Stephen Chia,Jie Li,Fei Ma et al.
Stephen Chia et al.
Aim: Ribociclib + nonsteroidal aromatase inhibitor (NSAI) and abemaciclib + endocrine therapy (ET) are approved for high-risk hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) early breast cancer based ...
Adherence, duration and healthcare costs in a real-world population of patients with acromegaly [0.03%]
生长抑素类似物治疗肢端肥大症的依从性、疗程及医疗费用
Tiffany P Quock,Eunice Chang,Ashis K Das et al.
Tiffany P Quock et al.
Aim: The aim of this study was to describe treatment patterns among patients with acromegaly who are newly treated with acromegaly medical therapy. Materials & methods: Data from IQVIA Pharmetrics Plus® Database from 1 January 2013 to 30 J...
Confirmatory long-term efficacy and safety results of ataluren in patients with nmDMD from Study 041, an international, randomized, double-blind, placebo-controlled, Phase III trial [0.03%]
NM型DMD患者的ataluren长期有效性与安全性的确证结果：一项国际性、随机（双盲）、安慰剂对照的III期临床试验（研究041）
Dmitry Vlodavets,Shiwen Wu,Anna Kostera-Pruszczyk et al.
Dmitry Vlodavets et al.
Aim: To report the efficacy and safety of ataluren in patients with nonsense mutation Duchenne muscular dystrophy (nmDMD) from the phase III, 72-week, placebo-controlled period of Study 041. Materials & methods: Inclusion criteria: boys wit...
Transportability of nonlocal real-world evidence and its relevance to health technology assessment: a primer [0.03%]
真实世界证据的可传递性及其对卫生技术评估的相关性：入门知识概述
Alind Gupta,Stephen Duffield,Cal Shephard et al.
Alind Gupta et al.
Real-world evidence (RWE) from outside Canada or the UK is sometimes included in submissions to health technology assessments by Canada's Drug Agency/L'Agence des médicaments du Canada (CDA-AMC) and National Institute for Health and Care E...